MEHA:NASDAQFunctional Brands, Inc. Analysis
Data as of 2026-04-17 - not real-time
$0.13
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Functional Brands Inc. (MEHA) is trading at $0.125, well below its 20‑day SMA of $0.159 and the DCF‑derived fair value of $0.322, suggesting a significant discount. Technical indicators are bearish: the MACD histogram is negative, the signal line is bearish, and the price sits below both the 20‑day and 50‑day SMAs, while the RSI at 36 hints at a near‑oversold condition. Volatility is extreme, with a 30‑day swing of 139% and a beta of 2.4, exposing the stock to sharp price swings. Fundamentals are weak – revenue fell 11% year‑over‑year, operating margin is –76%, and operating cash flow is negative, though free cash flow turned positive at $0.56 M. The balance sheet shows a debt‑to‑equity ratio of 173, indicating heavy leverage, but cash on hand nearly matches total debt. Recent news points to strategic moves, such as expanding international distribution of the P2i™ by Kirkman brand through iHerb and participation in the 38th Annual ROTH Conference, which could broaden market reach. However, the company has no dividend and a market cap of roughly $3 M, underscoring its micro‑cap status. The confluence of a deeply discounted price, high risk metrics, and ongoing operational challenges makes MEHA a high‑risk, value‑oriented play.
Given the “Extreme Greed” sentiment in the broader market, investors may be tempted by the low price, but the combination of bearish technicals, substantial debt, and volatile trading suggests caution. A potential upside exists if the international expansion gains traction and the company can stabilize margins, but this would likely require a longer horizon.
Given the “Extreme Greed” sentiment in the broader market, investors may be tempted by the low price, but the combination of bearish technicals, substantial debt, and volatile trading suggests caution. A potential upside exists if the international expansion gains traction and the company can stabilize margins, but this would likely require a longer horizon.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- Bearish MACD and price below short‑term SMAs
- High beta (2.4) and extreme 30‑day volatility
- Proximity to technical support at $0.106
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Undervalued relative to DCF fair value
- International distribution expansion (iHerb partnership)
- Improving free cash flow despite operating losses
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- Potential upside if margin improvement materializes
- Defensive consumer sector backdrop
- Significant price discount offering upside potential
Key Metrics & Analysis
Financial Health
Revenue Growth-11.00%
Profit Margin11.47%
P/E Ratio12.5
ROE106.62%
ROA-10.74%
Debt/Equity172.85
P/B Ratio1.5
Op. Cash Flow$-1271544
Free Cash Flow$562.8K
Technical Analysis
TrendBearish
RSI36.0
Support$0.11
Resistance$0.21
MA 20$0.16
MA 50$0.18
MA 200$0.29
MACDBearish
VolumeIncreasing
Fear & Greed Index89.39
Valuation
Fair Value$0.32
GradeUndervalued
TypeValue
Risk Assessment
Beta2.42
Volatility139.48%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.